AUG 6, 2026 · JOURNAL ARTICLE
Circulating asprosin as a biomarker for glycemic progression in systemic metabolic disorders
International Journal of Endocrinology
A well-designed case-control study with clear biochemical findings and diagnostic ROC performance, but limited by cross-sectional design, moderate sample size, and lack of prospective validation for predictive utility.
Reported
Sample size120
p-value (metabolic syndrome vs co…p < 0.001
AUC (metabolic syndrome with pred…0.863